Market Cap 382.49B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.71
Forward PE 15.14
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 9,912,770
Avg Vol 6,162,082
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 86%
Beta 0.32
Analysts Strong Sell
Price Target $251.55

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
MomentumCapitall
MomentumCapitall Jun. 23 at 2:51 AM
$ABBV $SOFI $QS $DKNG is trading in a way that reflects AI momentum continuation. I am staying disciplined and letting the chart confirm the narrative.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 23 at 2:28 AM
$SLS $ABBV $PFE $PFE I am more excited about the bidding war behind the scenes than ever before because in last few months We have seen a floor set for a bare minimum single potential Blockbuster phase 3 drug asset at $10 Billion. What are the true implications of an Oncology Platforms that can tackle 40+ different cancer types with an unprecedented Ad Infinitum Dosage schedule for 3 plus year with CURATIVE outcome? First comes the Trigger 80Th event that triggers the Top line data for Regal Pivotal Registrational phase 3. My Long Brothers and Sisters I have moved past charting and modeling scenarios to final valuation of this juggernaut unfolding right before our own eyes. Be encouraged by what’s going on in the Biotechnology sector. Last week we saw 10 deals. First day of the week today, We already saw the biggest acquisition by AbbVie in an over a decade. SLS Valuation will Top $50 Billion when the bidding war is over. Mark this post, it’s coming sooner than you all think ✌️🙏❤️‍🩹
0 · Reply
MarketGladiator
MarketGladiator Jun. 23 at 12:08 AM
My position in $SLV $ABBV $NASA $LKNCY $EBS is based on retail sentiment crowding. Volatility is expected, but the structure still looks intact.
0 · Reply
topstockalerts
topstockalerts Jun. 22 at 11:15 PM
$ABBV I’m starting to think this story has another chapter.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 22 at 10:38 PM
$ABBV Share Price: $229.96 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $4.97 – $6.14 Target Zone: $8.05 – $9.84 Potential Upside: 53% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBulll
WallStreetBulll Jun. 22 at 10:38 PM
Still holding $MSTR $ABBV $MXL $ACN. The market is pricing in long-term conviction holding, but I think the longer-term story is still developing.
0 · Reply
MarketCompasss
MarketCompasss Jun. 22 at 10:25 PM
Still holding $CLOV $NOK $RZLV $ABBV. The market is pricing in AI momentum continuation, but I think the longer-term story is still developing.
1 · Reply
FlockOfSeagulls
FlockOfSeagulls Jun. 22 at 8:23 PM
$ABBV Thanks for the bump in share price today. We unloaded all of our buys from the last 3 months. You guys put yourself out of the running for SLS which has a P3 in AML nearly complete for a P2 that is a ways off. Say goodbye to 80% of your Venclexta revenue.
0 · Reply
Mantraset3
Mantraset3 Jun. 22 at 8:19 PM
$ABBV this is a good company
0 · Reply
mikeywo
mikeywo Jun. 22 at 8:07 PM
$CNTB If $CTNB has superior efficacy and safety to $APGE in the atopic dermatitis arena and can compete with Dupixent in the Asthma space obviously the market does not know this yet and obviously $ABBV didn’t know it either or why pay 10B for a company that drug is going to be second choice behind Rademikibart. It’s time Barry either resigns or gets off his ass and find people who can get this drug known to the big players and analyst who control the bio market. 124M market cap is absolutely ridiculous.
3 · Reply
Latest News on ABBV
AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 12 hours ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 13 hours ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 13 hours ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 13 hours ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 15 hours ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 15 hours ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 15 hours ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie near deal to acquire Apogee Therapeutics, FT reports

2026-06-22T09:00:15.000Z - 17 hours ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 4 days ago

AbbVie Declares Quarterly Dividend


AbbVie announces EC authorizes expanded label for Venclyxto

2026-05-29T13:20:36.000Z - 24 days ago

AbbVie announces EC authorizes expanded label for Venclyxto


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 26 days ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 7 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 7 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation


MomentumCapitall
MomentumCapitall Jun. 23 at 2:51 AM
$ABBV $SOFI $QS $DKNG is trading in a way that reflects AI momentum continuation. I am staying disciplined and letting the chart confirm the narrative.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 23 at 2:28 AM
$SLS $ABBV $PFE $PFE I am more excited about the bidding war behind the scenes than ever before because in last few months We have seen a floor set for a bare minimum single potential Blockbuster phase 3 drug asset at $10 Billion. What are the true implications of an Oncology Platforms that can tackle 40+ different cancer types with an unprecedented Ad Infinitum Dosage schedule for 3 plus year with CURATIVE outcome? First comes the Trigger 80Th event that triggers the Top line data for Regal Pivotal Registrational phase 3. My Long Brothers and Sisters I have moved past charting and modeling scenarios to final valuation of this juggernaut unfolding right before our own eyes. Be encouraged by what’s going on in the Biotechnology sector. Last week we saw 10 deals. First day of the week today, We already saw the biggest acquisition by AbbVie in an over a decade. SLS Valuation will Top $50 Billion when the bidding war is over. Mark this post, it’s coming sooner than you all think ✌️🙏❤️‍🩹
0 · Reply
MarketGladiator
MarketGladiator Jun. 23 at 12:08 AM
My position in $SLV $ABBV $NASA $LKNCY $EBS is based on retail sentiment crowding. Volatility is expected, but the structure still looks intact.
0 · Reply
topstockalerts
topstockalerts Jun. 22 at 11:15 PM
$ABBV I’m starting to think this story has another chapter.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 22 at 10:38 PM
$ABBV Share Price: $229.96 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $4.97 – $6.14 Target Zone: $8.05 – $9.84 Potential Upside: 53% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WallStreetBulll
WallStreetBulll Jun. 22 at 10:38 PM
Still holding $MSTR $ABBV $MXL $ACN. The market is pricing in long-term conviction holding, but I think the longer-term story is still developing.
0 · Reply
MarketCompasss
MarketCompasss Jun. 22 at 10:25 PM
Still holding $CLOV $NOK $RZLV $ABBV. The market is pricing in AI momentum continuation, but I think the longer-term story is still developing.
1 · Reply
FlockOfSeagulls
FlockOfSeagulls Jun. 22 at 8:23 PM
$ABBV Thanks for the bump in share price today. We unloaded all of our buys from the last 3 months. You guys put yourself out of the running for SLS which has a P3 in AML nearly complete for a P2 that is a ways off. Say goodbye to 80% of your Venclexta revenue.
0 · Reply
Mantraset3
Mantraset3 Jun. 22 at 8:19 PM
$ABBV this is a good company
0 · Reply
mikeywo
mikeywo Jun. 22 at 8:07 PM
$CNTB If $CTNB has superior efficacy and safety to $APGE in the atopic dermatitis arena and can compete with Dupixent in the Asthma space obviously the market does not know this yet and obviously $ABBV didn’t know it either or why pay 10B for a company that drug is going to be second choice behind Rademikibart. It’s time Barry either resigns or gets off his ass and find people who can get this drug known to the big players and analyst who control the bio market. 124M market cap is absolutely ridiculous.
3 · Reply
CapitalEdgee
CapitalEdgee Jun. 22 at 7:52 PM
Still holding $PYPL $ABBV $SYM $BTC $PATH. The market is pricing in risk management focus, but I think the longer-term story is still developing.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 22 at 7:52 PM
$APGE congrats on the $ABBV buyout. $10B, nice 🏦
0 · Reply
pvll
pvll Jun. 22 at 6:55 PM
$ABBV good on ABBV for putting AI in their pills! Now turn your pill factories into data centers.
0 · Reply
breakoutstock
breakoutstock Jun. 22 at 6:47 PM
$NKTR pretty obvious they turned down an offer from $ABBV thid is a far superior drug. 🚀
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 6:18 PM
$ABBV just purchased $APGE for ELEVEN BILLION HOLY MOLY!! $VSEE has potential buyout or acquisition in place! EITHER WITH NASA OR ANOTHER US GOVERNMENT CONTRACT SOON HOLD EXTREMELY
0 · Reply
JFDI
JFDI Jun. 22 at 5:29 PM
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 22 at 5:28 PM
$SYRE 25% Trim Will ride to FDA approve Wutch $APGE $ABBV
0 · Reply
WallStWireAds
WallStWireAds Jun. 22 at 5:09 PM
$NVCT After Lilly and AbbVie, Haisco Picks Nuvectis Pharma for $1.46B Deal Spanning Two Late-Stage Assets with Best-in-Class Potential https://www.bioreview.com/after-lilly-and-abbvie-haisco-picks-nuvectis-pharma-for-1-46b-deal-spanning-two-late-stage-assets-with-best-in-class-potential/ $ABBV $LLY $NVS
0 · Reply
Gramma
Gramma Jun. 22 at 4:52 PM
$ABBV wow!!!
0 · Reply
usiv
usiv Jun. 22 at 4:44 PM
$ABBV it’s a weekly and daily breakout today.
0 · Reply
scalesojustice
scalesojustice Jun. 22 at 4:34 PM
$SLS $ABBV Buys APGE for 10.9 B and market cap rises 28 B. Money makes money....
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 22 at 4:15 PM
$SLS $ABBV $PFE $BMY 3 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Ptizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data after T1 halt= $120.00+ Longs are about to witness the most consequential and contested acquisition it has seen in a generation. Hold with conviction! ✌️🙏❤️‍🩹
0 · Reply